<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390375</url>
  </required_header>
  <id_info>
    <org_study_id>DW-0929_P301</org_study_id>
    <nct_id>NCT02390375</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the DW0929 in patients&#xD;
      with primary hypercholesterolemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C level</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">348</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DW-0929</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-0929</intervention_name>
    <description>5/10mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-0929</intervention_name>
    <description>10/10mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-0929</intervention_name>
    <description>20/10mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>5mg F/U study: DW-0929 5/10mg</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10mg F/U study: DW-0929 10/10mg</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20mg F/U study: DW-0929 20/10mg</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult over 19years&#xD;
&#xD;
          -  Patients with primary hypercholesterolemia whose LDL-C level is below 250mg/dL and TG&#xD;
             level is below 350mg/dL&#xD;
&#xD;
          -  Patients whose LDL-C level is under 'Anti- dyslipidemia drug administration considered&#xD;
             standard' of NCEP ATP III(2004)&#xD;
&#xD;
          -  Those who voluntarily written consent to participate in this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Severe renal impairment(CrCl&lt;30mL/min)&#xD;
&#xD;
          -  Those who have active liver disease and whose ALT, AST levels greater than twice the&#xD;
             upper limit of normal&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0mg/dL&#xD;
&#xD;
          -  Those who have been geunyukbyeong or rhabdomyolysis caused by using statin or have&#xD;
             hypersensitivity to ezetimibe&#xD;
&#xD;
          -  Combined cyclosporine -treated patients&#xD;
&#xD;
          -  HbA1c ≥ 9%&#xD;
&#xD;
          -  TSH ≥ 1.5 X ULN&#xD;
&#xD;
          -  HIV-positive person&#xD;
&#xD;
          -  Congestive heart failure patients classified as NYHA Class III or IV&#xD;
&#xD;
          -  Patients with uncontrolled arrhythmias&#xD;
&#xD;
          -  Patients who have malignant tumors needed chemotherapy, radiation therapy, etc.&#xD;
&#xD;
          -  Blood clotting disorders&#xD;
&#xD;
          -  Patients who had a myocardial infarction within 6 months or cardiovascular bypass&#xD;
             surgery, patients who have underwent angioplasty&#xD;
&#xD;
          -  Patients who had a history of anxiety or severe typical peripheral arterial disease&#xD;
             within three months&#xD;
&#xD;
          -  Women of childbearing age who don't agree with contraception during this clinical&#xD;
             trials&#xD;
&#xD;
          -  Pregnant women or nursing mothers&#xD;
&#xD;
          -  Those who take the drug in combination taboo&#xD;
&#xD;
          -  Who have been treated for another investigational drug within 30 days&#xD;
&#xD;
          -  Unsuitable characters in a clinical trial to test self- determination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boramae Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak-gu</state>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

